USFDA Nod Opens New Growth Avenue for $AUROPHARMA

$AUROPHARMA remained in focus after receiving final USFDA approval for Tofacitinib Tablets (5 mg and 10 mg), a generic version of Pfizer’s Xeljanz used to treat rheumatoid arthritis and other autoimmune disorders. The approval allows the company to immediately launch the product in the U.S. market, providing access to a sizeable revenue opportunity and further strengthening its generics portfolio. The development is seen as positive for Aurobindo’s U.S. business as it continues to expand its pipeline of complex and high-value products.